Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension

King, NE; Brittain, E

Brittain, E (通讯作者),Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Med Ctr, 2525 West End Bldg,Room Suite 300-A, Nashville, TN 37232 USA.

PULMONARY CIRCULATION, 2022; 12 (1):

Abstract

Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH-LHD) has no specific therapies and pulmonary arterial hyper......

Full Text Link